393 Views

A Case Based Discussion: Individualizing Localized Prostate Cancer Treatment Decisions with the Oncotype DX® GPS™ Assay

Friday, May 13, 2022

9:30 AM – 10:30 AM

Location: S&T Hall: Booth 1043

Presenter(s)

Understand the importance of assessing risk of adverse pathology in making treatment decisions for localized prostate cancer.
Review the development of the Oncotype DX Genomic Prostate Score® (GPS™) assay
Understand how experts use the GPS assay to help inform management and treatment decisions in localized prostate cancer patients

Sponsored by: Exact Sciences / Oncotype DX